Waleed Barakat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Waleed Barakat has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Rasha Abdel-Ghany
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
4 shared publicationsShimaa M. Elshazly
A Department of Pharmacology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
4 shared publications- Markus Schwaninger
Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lubeck, Lubeck, Germany
3 shared publications Shimaa Anis
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
3 shared publicationsAhmed Bihery
Department of Tropical Medicine, Faculty of Medicine, Zagazig University, Egypt
2 shared publications- Amr A. A. Mahmoud
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Dual SSRI and Neurotrophic Strategy for Ischemic Stroke: Comparative and Combined Effects of Paroxetine, Fluoxetine, and Cerebrolysin
BackgroundIschemic stroke is a leading cause of neurological disability, characterized by oxidative stress, inflammation, and apoptosis. This study evaluated the neuroprotective effects of two antidepressant drugs (paroxetine, fluoxetine), and cerebrolysin—alone and in combination—in a mouse model of focal cortical ischemia (dMCAO).MethodsSeventy male BALB/c mice were randomly assigned to seven groups: Sham, dMCAO, Paroxetine (P), Fluoxetine (F), Cerebrolysin (C), Paroxetine + Cerebrolysin (P+C), and Fluoxetine + Cerebrolysin (F+C). Treatments were administered for 7 days. Neurological scores, behavioral tests, histopathology, oxidative stress markers, inflammatory cytokines, and molecular signaling pathways were assessed.ResultsAll treatment groups showed significant improvement over dMCAO in neuroscore, motor/sensorimotor performance, and histological preservation. Combination therapies (P+C and F+C) demonstrated superior outcomes compared to monotherapies. MDA levels decreased and SOD activity increased in treatment groups compared to dMCAO group. NF-κB, TNF-α, IL-6, β-arrestin-2, and caspase-3 were downregulated, while Akt and 5-HT levels were elevated in treatment groups compared to dMCAO group.ConclusionParoxetine, fluoxetine, and cerebrolysin confer neuroprotection in ischemic stroke. Interestingly, both paroxetine and fluoxetine exerted similar neuroprotective effects which rules out any additional influence exerted through GRK2 inhibition via paroxetine compared to fluoxetine. Combining paroxetine or fluoxetine with cerebrolysin enhanced the neuroprotective efficacy.
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDual SSRI and Neurotrophic Strategy for Ischemic Stroke: Comparative and Combined Effects of Paroxetine, Fluoxetine, and Cerebrolysin
BackgroundIschemic stroke is a leading cause of neurological disability, characterized by oxidative stress, inflammation, and apoptosis. This study evaluated the neuroprotective effects of two antidepressant drugs (paroxetine, fluoxetine), and cerebrolysin—alone and in combination—in a mouse model of focal cortical ischemia (dMCAO).MethodsSeventy male BALB/c mice were randomly assigned to seven groups: Sham, dMCAO, Paroxetine (P), Fluoxetine (F), Cerebrolysin (C), Paroxetine + Cerebrolysin (P+C), and Fluoxetine + Cerebrolysin (F+C). Treatments were administered for 7 days. Neurological scores, behavioral tests, histopathology, oxidative stress markers, inflammatory cytokines, and molecular signaling pathways were assessed.ResultsAll treatment groups showed significant improvement over dMCAO in neuroscore, motor/sensorimotor performance, and histological preservation. Combination therapies (P+C and F+C) demonstrated superior outcomes compared to monotherapies. MDA levels decreased and SOD activity increased in treatment groups compared to dMCAO group. NF-κB, TNF-α, IL-6, β-arrestin-2, and caspase-3 were downregulated, while Akt and 5-HT levels were elevated in treatment groups compared to dMCAO group.ConclusionParoxetine, fluoxetine, and cerebrolysin confer neuroprotection in ischemic stroke. Interestingly, both paroxetine and fluoxetine exerted similar neuroprotective effects which rules out any additional influence exerted through GRK2 inhibition via paroxetine compared to fluoxetine. Combining paroxetine or fluoxetine with cerebrolysin enhanced the neuroprotective efficacy.
- Retraction
- 28 September 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 177018
Retraction notice to “Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade" [Eur. J. Pharmacol 724 (2014) 43–50]
- 28 September 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 177018
RetractionRetraction notice to “Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade" [Eur. J. Pharmacol 724 (2014) 43–50]
- 3 July 2023
- Published by SAGE Publications in Journal of Thermoplastic Composite Materials
- Vol. 37 (3) , 885-909
Optimization of electrospun chitosan/polyethylene oxide hybrid nanofibril composite via response surface methodology
The present study is an attempt to optimize the electrospinning parameters to fabricate chitosan/polyethylene oxide hybrid nanofiber composite with minimum diameter and coefficient of variation (homogeneity) by using response surface methodology (RSM). Based on central composite design (CCD), four factors (the chitosan/PEO ratio, the applied voltage, the needle-to-collector distance, and the spinning angle) was applied to evaluate the individual and combined effects of the parameters on the average diameter of nanofibers. Chitosan (CH) was blended with Polyethylene oxide (PEO) at weight ratios of 1:1, 2:1, 3:1, 4:1, and 5:1. As the composition ratio of chitosan was reduced, the viscosity of the chitosan/PEO blend solution also dropped. The RSM model identified the following conditions as necessary to produce the desired and most uniform CS/PEO fiber diameter: a CS/PEO blend ratio of 2:1 (w/w), a voltage of 25 kV, a distance of 20 cm, and a spinning angle of 45°. The average nanofiber diameter and homogeneity under these conditions were calculated to be 73 nm and 20.5%, respectively, compared to the predicted values of 71 nm and 15.58%, respectively.
- 3 July 2023
- Published by SAGE Publications in Journal of Thermoplastic Composite Materials
- Vol. 37 (3) , 885-909
Optimization of electrospun chitosan/polyethylene oxide hybrid nanofibril composite via response surface methodology
The present study is an attempt to optimize the electrospinning parameters to fabricate chitosan/polyethylene oxide hybrid nanofiber composite with minimum diameter and coefficient of variation (homogeneity) by using response surface methodology (RSM). Based on central composite design (CCD), four factors (the chitosan/PEO ratio, the applied voltage, the needle-to-collector distance, and the spinning angle) was applied to evaluate the individual and combined effects of the parameters on the average diameter of nanofibers. Chitosan (CH) was blended with Polyethylene oxide (PEO) at weight ratios of 1:1, 2:1, 3:1, 4:1, and 5:1. As the composition ratio of chitosan was reduced, the viscosity of the chitosan/PEO blend solution also dropped. The RSM model identified the following conditions as necessary to produce the desired and most uniform CS/PEO fiber diameter: a CS/PEO blend ratio of 2:1 (w/w), a voltage of 25 kV, a distance of 20 cm, and a spinning angle of 45°. The average nanofiber diameter and homogeneity under these conditions were calculated to be 73 nm and 20.5%, respectively, compared to the predicted values of 71 nm and 15.58%, respectively.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2331
Abstract 2331: Metabolic profiling of pre and post treatment ovarian cancer tissues using in situ mass spectrometry imaging
Chemotherapy resistance represents a major problem in ovarian cancer prognosis and reliable indicators of chemotherapy sensitivity remain an unmet need. Here, we examined metabolic profiles of pre- and post-neoadjuvant chemotherapy (NACT) tumor samples from patients with high-grade serous ovarian cancer (HGSC). We performed spatially resolved, desorption electrospray ionization-mass spectrometry (DESI-MS) on sections from clinically annotated HGSC samples collected according to a laparoscopic triage algorithm from patients pre- and post-NACT. Patients were considered to be either excellent (ER) if they presented complete response or only microscopic disease left at interval surgery, or poor responders (PR) if they presented stable or progressive disease after NACT. Tumor tissues from 50 patients (29 ER and 21 PR, 13 ER matched pre and post NACT, 13 PR matched pre and post-NACT) were eligible for the analyses Data relative to the detected metabolites, were collected from epithelium and stroma separately. We first identified differentially upregulated metabolites in ER and PR groups and performed pathway analysis. The over-represented pathways in the chemo-naïve PR tissues included the nucleotide metabolism pathway in epithelial areas, and degradation of cysteine and homocysteine, metabolism of amino acids and derivatives, as well as sulfur amino acids metabolism in the stromal areas (p values FDR adjusted 0.045). In general, both the epithelium and stroma of PR tissues of chemo-naïve tumors, contained a higher number and a higher variety of lipid species compared with ER tissues. In post-NACT tumor epithelial areas, there was global downregulation of metabolites across all patient samples, compared to the pre-chemo specimens; this was more evident in ER patients. In post-NACT tumors from PR patients, glutathione synthesis and recycling pathway, and sulfite oxidation to sulfate pathway and many glycerolipids species were upregulated in the epithelium, while phosphatidic acids were upregulated in the stroma. Lastly, we evaluated the predictive power of the metabolic data extracted by the epithelial areas of chemo-naïve tissues, in classifying patients as ER or PR. We used 10-fold cross-validation to create a ridge regression model for the classification of ER and PR samples from pre-NACT tumor tissues. This model, based on 78 differentially expressed metabolites (small molecules and lipids), correctly classified patients as ER or PR with an accuracy of 76.2% (sensitivity 84.6% and specificity 62.5%). Our findings indicate altered metabolic pathways in ovarian cancer tissues based on response to NACT. The identification of differentially activated pathways, such as sulfate metabolism and glutathione metabolism in tumors with poor response, suggest novel actionable targets to overcome chemotherapy resistance in patients with HGSC. Citation Format: Sara Corvigno, Meredith Spraldin, Michael Keating, Sunil Badal, Igor Pereira, Elaine Stur, Nicholas Bateman, Waleed Barakat, Thomas Conrads, Sanghoon Lee, George Maxwell, Susan K. Lutgendorf, Premal Thaker, Jinsong Liu, Nicole Fleming, Katheleen Darcy, Livia S. Eberlin, Anil K. Sood. Metabolic profiling of pre and post treatment ovarian cancer tissues using in situ mass spectrometry imaging [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2331.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2331
Open AccessAbstract 2331: Metabolic profiling of pre and post treatment ovarian cancer tissues using in situ mass spectrometry imaging
Chemotherapy resistance represents a major problem in ovarian cancer prognosis and reliable indicators of chemotherapy sensitivity remain an unmet need. Here, we examined metabolic profiles of pre- and post-neoadjuvant chemotherapy (NACT) tumor samples from patients with high-grade serous ovarian cancer (HGSC). We performed spatially resolved, desorption electrospray ionization-mass spectrometry (DESI-MS) on sections from clinically annotated HGSC samples collected according to a laparoscopic triage algorithm from patients pre- and post-NACT. Patients were considered to be either excellent (ER) if they presented complete response or only microscopic disease left at interval surgery, or poor responders (PR) if they presented stable or progressive disease after NACT. Tumor tissues from 50 patients (29 ER and 21 PR, 13 ER matched pre and post NACT, 13 PR matched pre and post-NACT) were eligible for the analyses Data relative to the detected metabolites, were collected from epithelium and stroma separately. We first identified differentially upregulated metabolites in ER and PR groups and performed pathway analysis. The over-represented pathways in the chemo-naïve PR tissues included the nucleotide metabolism pathway in epithelial areas, and degradation of cysteine and homocysteine, metabolism of amino acids and derivatives, as well as sulfur amino acids metabolism in the stromal areas (p values FDR adjusted 0.045). In general, both the epithelium and stroma of PR tissues of chemo-naïve tumors, contained a higher number and a higher variety of lipid species compared with ER tissues. In post-NACT tumor epithelial areas, there was global downregulation of metabolites across all patient samples, compared to the pre-chemo specimens; this was more evident in ER patients. In post-NACT tumors from PR patients, glutathione synthesis and recycling pathway, and sulfite oxidation to sulfate pathway and many glycerolipids species were upregulated in the epithelium, while phosphatidic acids were upregulated in the stroma. Lastly, we evaluated the predictive power of the metabolic data extracted by the epithelial areas of chemo-naïve tissues, in classifying patients as ER or PR. We used 10-fold cross-validation to create a ridge regression model for the classification of ER and PR samples from pre-NACT tumor tissues. This model, based on 78 differentially expressed metabolites (small molecules and lipids), correctly classified patients as ER or PR with an accuracy of 76.2% (sensitivity 84.6% and specificity 62.5%). Our findings indicate altered metabolic pathways in ovarian cancer tissues based on response to NACT. The identification of differentially activated pathways, such as sulfate metabolism and glutathione metabolism in tumors with poor response, suggest novel actionable targets to overcome chemotherapy resistance in patients with HGSC. Citation Format: Sara Corvigno, Meredith Spraldin, Michael Keating, Sunil Badal, Igor Pereira, Elaine Stur, Nicholas Bateman, Waleed Barakat, Thomas Conrads, Sanghoon Lee, George Maxwell, Susan K. Lutgendorf, Premal Thaker, Jinsong Liu, Nicole Fleming, Katheleen Darcy, Livia S. Eberlin, Anil K. Sood. Metabolic profiling of pre and post treatment ovarian cancer tissues using in situ mass spectrometry imaging [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2331.
- Open Access
- 11 October 2020
- Published by Egyptian Knowledge Bank in Zagazig Journal of Pharmaceutical Sciences
Modulation of advanced glycation endproducts (AGEs) signaling in experimentally induced stroke in mice.
Stroke is a leading cause of death and permanent disability in adults worldwide. Advanced glycation endproducts (AGEs) are known to be increased in several chronic diseases and induce inflammation and protein crosslinking. The current study was designed to investigate the protective effect of benfotiamine, perindopril (at a sub-hypotensive dose), and alagebrium on experimentally induced stroke in mice. All drugs were administered for 9 days starting one week before middle cerebral artery occlusion (MCAO). Benfotiamine, perindopril and alagebrium ameliorated the deleterious effects of MCAO as indicated by the improvement in the performance of the animals in behavior tests and the reduction in brain infarction. This was associated with normalization of the levels of receptor for advanced glycation end products (RAGE) and its soluble form sRAGE that were changed following MCAO. In addition, benfotiamine, perindopril and alagebrium corrected the upregulation in the downstream effectors TNF-α and VCAM-1. The results of the current study represent a new indication for benfotiamine, perindopril, alagebrium in the management of ischemic stroke.
- 11 October 2020
- Published by Egyptian Knowledge Bank in Zagazig Journal of Pharmaceutical Sciences
Open AccessModulation of advanced glycation endproducts (AGEs) signaling in experimentally induced stroke in mice.
Stroke is a leading cause of death and permanent disability in adults worldwide. Advanced glycation endproducts (AGEs) are known to be increased in several chronic diseases and induce inflammation and protein crosslinking. The current study was designed to investigate the protective effect of benfotiamine, perindopril (at a sub-hypotensive dose), and alagebrium on experimentally induced stroke in mice. All drugs were administered for 9 days starting one week before middle cerebral artery occlusion (MCAO). Benfotiamine, perindopril and alagebrium ameliorated the deleterious effects of MCAO as indicated by the improvement in the performance of the animals in behavior tests and the reduction in brain infarction. This was associated with normalization of the levels of receptor for advanced glycation end products (RAGE) and its soluble form sRAGE that were changed following MCAO. In addition, benfotiamine, perindopril and alagebrium corrected the upregulation in the downstream effectors TNF-α and VCAM-1. The results of the current study represent a new indication for benfotiamine, perindopril, alagebrium in the management of ischemic stroke.
- 21 November 2018
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (2) , 165-175
Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions
Cancer is a broad term used to describe a large number of diseases characterized by uncontrolled cell proliferation that leads to tumor production. Cancer is associated with mutations in genes controlling proliferation and apoptosis, oxidative stress, fatty acid synthase (FAS) expression, and other mechanisms. Currently, most antineoplastic drugs have severe adverse effects and new effective and safe drugs are needed. This study aims to investigate the possible anticancer activity of rutin and orlistat which are both safely used clinically in humans against two breast cancer models (in vivo EAC and in vitro MCF7) and the pancreatic cancer cell line (PANC-1). Our results have shown that both rutin and orlistat exerted an in vivo anticancer activity as evidenced by the decrease in tumor volume, CEA level, cholesterol content, FAS, and the exerted antioxidant action (reduced MDA level and increased GSH content) and through histopathological examination. In addition, both were cytotoxic to MCF-7 and Panc-1 cell lines by promoting apoptosis. In conclusion, the anticancer activity of rutin and orlistat makes them promising candidates for cancer treatment alone or in combination with other anticancer drugs specially that they are used clinically with an acceptable safety profile.
- 21 November 2018
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (2) , 165-175
Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions
Cancer is a broad term used to describe a large number of diseases characterized by uncontrolled cell proliferation that leads to tumor production. Cancer is associated with mutations in genes controlling proliferation and apoptosis, oxidative stress, fatty acid synthase (FAS) expression, and other mechanisms. Currently, most antineoplastic drugs have severe adverse effects and new effective and safe drugs are needed. This study aims to investigate the possible anticancer activity of rutin and orlistat which are both safely used clinically in humans against two breast cancer models (in vivo EAC and in vitro MCF7) and the pancreatic cancer cell line (PANC-1). Our results have shown that both rutin and orlistat exerted an in vivo anticancer activity as evidenced by the decrease in tumor volume, CEA level, cholesterol content, FAS, and the exerted antioxidant action (reduced MDA level and increased GSH content) and through histopathological examination. In addition, both were cytotoxic to MCF-7 and Panc-1 cell lines by promoting apoptosis. In conclusion, the anticancer activity of rutin and orlistat makes them promising candidates for cancer treatment alone or in combination with other anticancer drugs specially that they are used clinically with an acceptable safety profile.
- 29 March 2018
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 391 (6) , 603-612
Effectiveness of arginase inhibitors against experimentally induced stroke
Stroke is a lethal disease, but it disables more than it kills. Stroke is the second leading cause of death and the most frequent cause of permanent disability in adults worldwide, with 90% of survivors having residual deficits. The pathophysiology of stroke is complex and involves a strong inflammatory response associated with oxidative stress and activation of several proteolytic enzymes. The current study was designed to investigate the effect of arginase inhibitors (L-citruline and L-ornithine) against ischemic stroke induced in rats by middle cerebral artery occlusion (MCAO). MCAO resulted in alteration in rat behavior, brain infarct, and edema associated with disruption of the blood-brain barrier (BBB). This was mediated through overexpression of arginase I and II, inducible NOS (iNOS), malondialdehyde (MDA), advanced glycation end products (AGEs), TNF-α, and IL-1β and downregulation of endothelial nitric oxide synthase (eNOS). Treatment with L-citruline and L-ornithine and the standard neuroprotective drug cerebrolysin ameliorated all the deleterious effects of stroke. These results indicate the possible use of arginase inhibitors in the treatment of stroke after suitable clinical trials are done.
- 29 March 2018
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 391 (6) , 603-612
Effectiveness of arginase inhibitors against experimentally induced stroke
Stroke is a lethal disease, but it disables more than it kills. Stroke is the second leading cause of death and the most frequent cause of permanent disability in adults worldwide, with 90% of survivors having residual deficits. The pathophysiology of stroke is complex and involves a strong inflammatory response associated with oxidative stress and activation of several proteolytic enzymes. The current study was designed to investigate the effect of arginase inhibitors (L-citruline and L-ornithine) against ischemic stroke induced in rats by middle cerebral artery occlusion (MCAO). MCAO resulted in alteration in rat behavior, brain infarct, and edema associated with disruption of the blood-brain barrier (BBB). This was mediated through overexpression of arginase I and II, inducible NOS (iNOS), malondialdehyde (MDA), advanced glycation end products (AGEs), TNF-α, and IL-1β and downregulation of endothelial nitric oxide synthase (eNOS). Treatment with L-citruline and L-ornithine and the standard neuroprotective drug cerebrolysin ameliorated all the deleterious effects of stroke. These results indicate the possible use of arginase inhibitors in the treatment of stroke after suitable clinical trials are done.
- 21 July 2017
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 390 (10) , 1061-1071
Anticancer activity of salicin and fenofibrate
Cancer refers to a disorder of cell proliferation that leads to tumor production. Cancer is usually treated by surgery, chemotherapeutic drugs, and radiation. Despite the presence of many anticancer drugs, cancer is still an uncontrolled disease and is a major cause of death worldwide. In addition, most anticancer drugs have severe side effects that can limit their use in some patients. This study aims to investigate the possible anticancer activity of two clinically used drugs: a natural antioxidant agent (salicin) and an antihyperlipidemic agent (fenofibrate) against two breast cancer models (in vivo EAC and in vitro MCF7) and the pancreatic cancer cell line (Panc-1).Our results have shown that both salicin and fenofibrate exerted an in vivo anticancer activity as evidenced by the decrease in tumor weight, tumor volume, CEA level, and reduced tumor cholesterol content through an antioxidant (reduced MDA level and increased GSH and catalase content) and an antiinflammatory activity (reduced TNF-∝ level). In addition, both salicin and fenofibrate were shown to be cytotoxic to MCF-7 and Panc-1 cell lines through activation of the caspase 3/7 apoptotic pathway.In conclusion, salicin and fenofibrate are promising anticancer drugs that are already used clinically with acceptable safety profile which can be incorporated into clinical trials to determine their possible application in cancer treatment.
- 21 July 2017
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 390 (10) , 1061-1071
Anticancer activity of salicin and fenofibrate
Cancer refers to a disorder of cell proliferation that leads to tumor production. Cancer is usually treated by surgery, chemotherapeutic drugs, and radiation. Despite the presence of many anticancer drugs, cancer is still an uncontrolled disease and is a major cause of death worldwide. In addition, most anticancer drugs have severe side effects that can limit their use in some patients. This study aims to investigate the possible anticancer activity of two clinically used drugs: a natural antioxidant agent (salicin) and an antihyperlipidemic agent (fenofibrate) against two breast cancer models (in vivo EAC and in vitro MCF7) and the pancreatic cancer cell line (Panc-1).Our results have shown that both salicin and fenofibrate exerted an in vivo anticancer activity as evidenced by the decrease in tumor weight, tumor volume, CEA level, and reduced tumor cholesterol content through an antioxidant (reduced MDA level and increased GSH and catalase content) and an antiinflammatory activity (reduced TNF-∝ level). In addition, both salicin and fenofibrate were shown to be cytotoxic to MCF-7 and Panc-1 cell lines through activation of the caspase 3/7 apoptotic pathway.In conclusion, salicin and fenofibrate are promising anticancer drugs that are already used clinically with acceptable safety profile which can be incorporated into clinical trials to determine their possible application in cancer treatment.
- Open Access
- 7 December 2016
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 15 (11) , 2371-2381
In vitro and in vivo hepatoprotective activity of extracts of aerial parts of Bidens pilosa L (Asteraceae)
In vitro and in vivo hepatoprotective activity of extracts of aerial parts of Bidens pilosa L (Asteraceae)
- 7 December 2016
- Published by African Journals Online (AJOL) in Tropical Journal of Pharmaceutical Research
- Vol. 15 (11) , 2371-2381
Open AccessIn vitro and in vivo hepatoprotective activity of extracts of aerial parts of Bidens pilosa L (Asteraceae)
In vitro and in vivo hepatoprotective activity of extracts of aerial parts of Bidens pilosa L (Asteraceae)